康众医疗2025年转亏 2021年上市募资5亿中信证券保荐

Core Viewpoint - Kangzhong Medical (688607.SH) reported a total operating revenue of 320.53 million yuan for the year 2025, reflecting a year-on-year growth of 7.52%. However, the company faced a net loss attributable to shareholders of 7.10 million yuan, compared to a profit of 17.65 million yuan in the previous year, indicating significant challenges in profitability amidst competitive pressures [1][3]. Financial Performance Summary - Total operating revenue reached 320.53 million yuan, up from 298.10 million yuan, marking a 7.52% increase [3]. - Operating profit was reported at -10.76 million yuan, down from 175.76 million yuan, with the change being not applicable due to the loss [3]. - Net profit attributable to shareholders was -7.10 million yuan, compared to 17.65 million yuan in the previous year, with the change being not applicable [3]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was -15.63 million yuan, down from 5.94 million yuan in the previous year, with the change being not applicable [3]. Factors Affecting Performance - The decline in profitability is attributed to intensified industry competition, leading the company to adjust pricing strategies to maintain market competitiveness. This, combined with a relatively rigid cost structure and delayed cost adjustments, resulted in a decrease in gross profit margin [1][3]. - The company has been actively responding to external market challenges by increasing R&D investments, accelerating project implementation, and establishing new subsidiaries, which contributed to rising expenses [1][3]. - Additionally, the company made special provisions for credit impairment losses due to litigation matters related to accounts receivable, following relevant accounting standards and a prudent approach [1][3].